Exact Mass: 543.342052
Exact Mass Matches: 543.342052
Found 324 metabolites which its exact mass value is equals to given mass value 543.342052,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
LysoPC(20:4(5Z,8Z,11Z,14Z)/0:0)
LysoPC(20:4(5Z,8Z,11Z,14Z)) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(20:4(5Z,8Z,11Z,14Z)), in particular, consists of one chain of arachidonic acid at the C-1 position. The arachidonic acid moiety is derived from animal fats and eggs. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins. [HMDB] LysoPC(20:4(5Z,8Z,11Z,14Z)) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(20:4(5Z,8Z,11Z,14Z)), in particular, consists of one chain of arachidonic acid at the C-1 position. The arachidonic acid moiety is derived from animal fats and eggs. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins.
LysoPC(20:4(8Z,11Z,14Z,17Z)/0:0)
LysoPC(20:4(8Z,11Z,14Z,17Z)) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(20:4(8Z,11Z,14Z,17Z)), in particular, consists of one chain of eicsoatetraenoic acid at the C-1 position. The eicsoatetraenoic acid moiety is derived from fish oils. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins. [HMDB] LysoPC(20:4(8Z,11Z,14Z,17Z)) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(20:4(8Z,11Z,14Z,17Z)), in particular, consists of one chain of eicsoatetraenoic acid at the C-1 position. The eicsoatetraenoic acid moiety is derived from fish oils. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins.
LysoPC(0:0/20:4(5Z,8Z,11Z,14Z))
LysoPC(0:0/20:4(5Z,8Z,11Z,14Z)) is a lysophosphatidylcholine, which is a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2 as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. There is also a phospholipase A1, which is able to cleave the sn-1 ester bond. Lysophosphatidylcholine has pro-inflammatory properties in vitro and it is known to be a pathological component of oxidized lipoproteins (LDL) in plasma and of atherosclerotic lesions. Recently, it has been found to have some functions in cell signalling, and specific receptors (coupled to G proteins) have been identified. It activates the specific phospholipase C that releases diacylglycerols and inositol triphosphate with resultant increases in intracellular Ca2+ and activation of protein kinase C. It also activates the mitogen-activated protein kinase in certain cell types. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. LysoPC(0:0/20:4(5Z,8Z,11Z,14Z)), in particular, consists of one chain of arachidonic acid at the C-2 position.
Arg Asn Val Arg
His Phe Ile Lys
Phe His Ile Lys
Phe His Lys Ile
Phe His Lys Leu
Phe His Leu Lys
Phe Ile His Lys
Phe Ile Lys His
Phe Lys His Ile
Phe Lys His Leu
Phe Lys Ile His
Phe Lys Leu His
Phe Leu His Lys
Phe Leu Lys His
Gly Arg Arg Arg
His Phe Lys Ile
His Phe Lys Leu
His Phe Leu Lys
His Ile Phe Lys
His Ile Lys Phe
His Lys Phe Ile
His Lys Phe Leu
His Lys Ile Phe
His Lys Leu Phe
His Leu Phe Lys
His Leu Lys Phe
Ile Phe His Lys
Ile Phe Lys His
Ile His Phe Lys
Ile His Lys Phe
Ile Ile Ile Trp
Ile Ile Leu Trp
Ile Ile Trp Ile
Ile Ile Trp Leu
Ile Lys Phe His
Ile Lys His Phe
Ile Lys Lys Arg
Ile Lys Gln Arg
C23H45N9O6 (543.3492630000001)
Ile Lys Arg Lys
Ile Lys Arg Gln
C23H45N9O6 (543.3492630000001)
Ile Leu Ile Trp
Ile Leu Leu Trp
Ile Leu Trp Ile
Ile Leu Trp Leu
Ile Gln Lys Arg
C23H45N9O6 (543.3492630000001)
Ile Gln Gln Arg
C22H41N9O7 (543.3128796000001)
Ile Gln Arg Lys
C23H45N9O6 (543.3492630000001)
Ile Gln Arg Gln
C22H41N9O7 (543.3128796000001)
Ile Arg Lys Lys
Ile Arg Lys Gln
C23H45N9O6 (543.3492630000001)
Ile Arg Gln Lys
C23H45N9O6 (543.3492630000001)
Ile Arg Gln Gln
C22H41N9O7 (543.3128796000001)
Ile Trp Ile Ile
Ile Trp Ile Leu
Ile Trp Leu Ile
Ile Trp Leu Leu
Lys Phe His Ile
Lys Phe His Leu
Lys Phe Ile His
Lys Phe Leu His
Lys His Phe Ile
Lys His Phe Leu
Lys His Ile Phe
Lys His Leu Phe
Lys Ile Phe His
Lys Ile His Phe
Lys Ile Lys Arg
Lys Ile Gln Arg
C23H45N9O6 (543.3492630000001)
Lys Ile Arg Lys
Lys Ile Arg Gln
C23H45N9O6 (543.3492630000001)
Lys Lys Ile Arg
Lys Lys Leu Arg
Lys Lys Arg Ile
Lys Lys Arg Leu
Lys Leu Phe His
Lys Leu His Phe
Lys Leu Lys Arg
Lys Leu Gln Arg
C23H45N9O6 (543.3492630000001)
Lys Leu Arg Lys
Lys Leu Arg Gln
C23H45N9O6 (543.3492630000001)
Lys Gln Ile Arg
C23H45N9O6 (543.3492630000001)
Lys Gln Leu Arg
C23H45N9O6 (543.3492630000001)
Lys Gln Arg Ile
C23H45N9O6 (543.3492630000001)
Lys Gln Arg Leu
C23H45N9O6 (543.3492630000001)
Lys Arg Ile Lys
Lys Arg Ile Gln
C23H45N9O6 (543.3492630000001)
Lys Arg Lys Ile
Lys Arg Lys Leu
Lys Arg Leu Lys
Lys Arg Leu Gln
C23H45N9O6 (543.3492630000001)
Lys Arg Gln Ile
C23H45N9O6 (543.3492630000001)
Lys Arg Gln Leu
C23H45N9O6 (543.3492630000001)
Leu Phe His Lys
Leu Phe Lys His
Leu His Phe Lys
Leu His Lys Phe
Leu Ile Ile Trp
Leu Ile Leu Trp
Leu Ile Trp Ile
Leu Ile Trp Leu
Leu Lys Phe His
Leu Lys His Phe
Leu Lys Lys Arg
Leu Lys Gln Arg
C23H45N9O6 (543.3492630000001)
Leu Lys Arg Lys
Leu Lys Arg Gln
C23H45N9O6 (543.3492630000001)
Leu Leu Ile Trp
Leu Leu Leu Trp
Leu Leu Trp Ile
Leu Leu Trp Leu
Leu Gln Lys Arg
C23H45N9O6 (543.3492630000001)
Leu Gln Gln Arg
C22H41N9O7 (543.3128796000001)
Leu Gln Arg Lys
C23H45N9O6 (543.3492630000001)
Leu Gln Arg Gln
C22H41N9O7 (543.3128796000001)
Leu Arg Lys Lys
Leu Arg Lys Gln
C23H45N9O6 (543.3492630000001)
Leu Arg Gln Lys
C23H45N9O6 (543.3492630000001)
Leu Arg Gln Gln
C22H41N9O7 (543.3128796000001)
Leu Trp Ile Ile
Leu Trp Ile Leu
Leu Trp Leu Ile
Leu Trp Leu Leu
Asn Arg Arg Val
Asn Arg Val Arg
Asn Val Arg Arg
Gln Ile Lys Arg
C23H45N9O6 (543.3492630000001)
Gln Ile Gln Arg
C22H41N9O7 (543.3128796000001)
Gln Ile Arg Lys
C23H45N9O6 (543.3492630000001)
Gln Ile Arg Gln
C22H41N9O7 (543.3128796000001)
Gln Lys Ile Arg
C23H45N9O6 (543.3492630000001)
Gln Lys Leu Arg
C23H45N9O6 (543.3492630000001)
Gln Lys Arg Ile
C23H45N9O6 (543.3492630000001)
Gln Lys Arg Leu
C23H45N9O6 (543.3492630000001)
Gln Leu Lys Arg
C23H45N9O6 (543.3492630000001)
Gln Leu Gln Arg
C22H41N9O7 (543.3128796000001)
Gln Leu Arg Lys
C23H45N9O6 (543.3492630000001)
Gln Leu Arg Gln
C22H41N9O7 (543.3128796000001)
Gln Gln Ile Arg
C22H41N9O7 (543.3128796000001)
Gln Gln Leu Arg
C22H41N9O7 (543.3128796000001)
Gln Gln Arg Ile
C22H41N9O7 (543.3128796000001)
Gln Gln Arg Leu
C22H41N9O7 (543.3128796000001)
Gln Arg Ile Lys
C23H45N9O6 (543.3492630000001)
Gln Arg Ile Gln
C22H41N9O7 (543.3128796000001)
Gln Arg Lys Ile
C23H45N9O6 (543.3492630000001)
Gln Arg Lys Leu
C23H45N9O6 (543.3492630000001)
Gln Arg Leu Lys
C23H45N9O6 (543.3492630000001)
Gln Arg Leu Gln
C22H41N9O7 (543.3128796000001)
Gln Arg Gln Ile
C22H41N9O7 (543.3128796000001)
Gln Arg Gln Leu
C22H41N9O7 (543.3128796000001)
Arg Gly Arg Arg
Arg Ile Lys Lys
Arg Ile Lys Gln
C23H45N9O6 (543.3492630000001)
Arg Ile Gln Lys
C23H45N9O6 (543.3492630000001)
Arg Ile Gln Gln
C22H41N9O7 (543.3128796000001)
Arg Lys Ile Lys
Arg Lys Ile Gln
C23H45N9O6 (543.3492630000001)
Arg Lys Lys Ile
Arg Lys Lys Leu
Arg Lys Leu Lys
Arg Lys Leu Gln
C23H45N9O6 (543.3492630000001)
Arg Lys Gln Ile
C23H45N9O6 (543.3492630000001)
Arg Lys Gln Leu
C23H45N9O6 (543.3492630000001)
Arg Leu Lys Lys
Arg Leu Lys Gln
C23H45N9O6 (543.3492630000001)
Arg Leu Gln Lys
C23H45N9O6 (543.3492630000001)
Arg Leu Gln Gln
C22H41N9O7 (543.3128796000001)
Arg Asn Arg Val
Arg Gln Ile Lys
C23H45N9O6 (543.3492630000001)
Arg Gln Ile Gln
C22H41N9O7 (543.3128796000001)
Arg Gln Lys Ile
C23H45N9O6 (543.3492630000001)
Arg Gln Lys Leu
C23H45N9O6 (543.3492630000001)
Arg Gln Leu Lys
C23H45N9O6 (543.3492630000001)
Arg Gln Leu Gln
C22H41N9O7 (543.3128796000001)
Arg Gln Gln Ile
C22H41N9O7 (543.3128796000001)
Arg Gln Gln Leu
C22H41N9O7 (543.3128796000001)
Arg Arg Gly Arg
Arg Arg Asn Val
Arg Arg Arg Gly
Arg Arg Val Asn
Arg Val Asn Arg
Arg Val Arg Asn
Val Asn Arg Arg
Val Arg Asn Arg
Val Arg Arg Asn
Trp Ile Ile Ile
Trp Ile Ile Leu
Trp Ile Leu Ile
Trp Ile Leu Leu
Trp Leu Ile Ile
Trp Leu Ile Leu
Trp Leu Leu Ile
Trp Leu Leu Leu
PC(20:4/0:0)
Arachidonyl lysolecithin
TETRADECYL 2-ACETAMIDO-2-DEOXY-3,4,6-TRI-O-ACETYL-β-D-GLUCOPYRANOSIDE
sodium hydrogen N,N-dibutyl-10-(sulphonatooxy)octadecanamidate
(2S)-N-[(4S,4aR,6R,8S,8aR)-6-[[(2R)-6-hydroxyoxan-2-yl]methyl]-8-methoxy-7,7-dimethyl-4a,6,8,8a-tetrahydro-4H-pyrano[3,2-d][1,3]dioxin-4-yl]-2-hydroxy-2-[(2R,5R,6R)-2-methoxy-5,6-dimethyl-4-methylideneoxan-2-yl]acetamide
(2S)-2-[[[5-[[methyl-(phenylmethyl)amino]-oxomethyl]-1H-imidazol-4-yl]-oxomethyl]amino]-6-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]hexanoic acid tert-butyl ester
(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-10-[[methyl-[(4-methyl-2,3-dihydro-1,4-benzoxazin-7-yl)methyl]amino]methyl]-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-14-one
C33H41N3O4 (543.3096906000001)
N-[(4R,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(2-phenylethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
C33H41N3O4 (543.3096906000001)
(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-10-[[methyl-[(4-methyl-2,3-dihydro-1,4-benzoxazin-7-yl)methyl]amino]methyl]-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-14-one
C33H41N3O4 (543.3096906000001)
(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-10-[[methyl-[(4-methyl-2,3-dihydro-1,4-benzoxazin-7-yl)methyl]amino]methyl]-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-14-one
C33H41N3O4 (543.3096906000001)
[2-hydroxy-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
2-aminoethyl [2-hydroxy-3-[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoxy]propyl] hydrogen phosphate
[2-butanoyloxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
(E)-3-hydroxy-2-[[(10Z,12Z)-2-hydroxyoctadeca-10,12-dienoyl]amino]undec-4-ene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxytridec-8-enoyl]amino]hexadeca-4,8-diene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxydodec-5-enoyl]amino]heptadeca-4,8-diene-1-sulfonic acid
(E)-3-hydroxy-2-[[(4Z,7Z)-2-hydroxyhexadeca-4,7-dienoyl]amino]tridec-4-ene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-(2-hydroxytridecanoylamino)hexadeca-4,8,12-triene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxytetradec-9-enoyl]amino]pentadeca-4,8-diene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-(2-hydroxypentadecanoylamino)tetradeca-4,8,12-triene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxyhexadec-7-enoyl]amino]trideca-4,8-diene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-(2-hydroxydodecanoylamino)heptadeca-4,8,12-triene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxypentadec-9-enoyl]amino]tetradeca-4,8-diene-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propan-2-yl] heptanoate
(4E,8E,12E)-3-hydroxy-2-(2-hydroxytetradecanoylamino)pentadeca-4,8,12-triene-1-sulfonic acid
[2-acetyloxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-propanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propan-2-yl] pentanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]propan-2-yl] propanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-butanoyloxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate
[1-acetyloxy-3-[2-aminoethoxy(hydroxy)phosphoryl]oxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate
[(2R)-2-hydroxy-3-[(7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[(2R)-2-hydroxy-3-[(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
1-Arachidonoyl-sn-glycero-3-phosphocholine
A lysophosphatidylcholine 20:4 in which the acyl group at position 1 is (5Z,8Z,11Z,14Z)-icosatetraenoyl (arachidonoyl) and the hydroxy group at position 2 is unsubstituted.
lysophosphatidylcholine 20:4
An acyl-sn-glycero-3-phosphocholine in which the remaining acyl group (position not specified) contains 20 carbons with 4 double bonds.
lysophosphatidylcholine(0:0/20:4)
A 2-acyl-sn-glycero-3-phosphocholine in which the 2-acyl group contains 20 carbons and 4 double bonds.
Lysophosphatidylcholine(20:4/0:0)
A 1-acyl-sn-glycero-3-phosphocholine in which the 1-acyl group contains 20 carbons and 4 double bonds.
phosphatidylethanolamine 22:4 zwitterion
A 1,2-diacyl-sn-glycero-3-phosphoethanolamine zwitterion in which the two acyl groups contain a total of 22 carbons and 4 double bonds.
1-[(8Z,11Z,14Z,17Z)-icosatetraenoyl]-sn-glycero-3-phosphocholine
A lysophosphatidylcholine 20:4 in which the the acyl group at position 1 is specified as (8Z,11Z,14Z,17Z)-icosatetraenoyl.
2-Arachidonoyl-sn-glycero-3-phosphocholine
A lysophosphatidylcholine 20:4 in which the acyl group is specified as arachidonoyl and is located at position 2.
MePC(19:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
PC(19:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
PE(22:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
MePC(18:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
6-benzyl-5,8,11-trihydroxy-9-isopropyl-13-(octan-2-yl)-3-(sec-butyl)-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-2-one
(2r)-2-hydroxy-3-{[(2s,7z)-2-methoxy-12-methyloctadeca-7,17-dien-5-ynoyl]oxy}propyl 2-(trimethylammonio)ethylphosphonate
(3r,6s,9s,13r)-6-benzyl-3-[(2s)-butan-2-yl]-5,8,11-trihydroxy-9-isopropyl-13-[(2s)-octan-2-yl]-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-2-one
beauverilide a
{"Ingredient_id": "HBIN017672","Ingredient_name": "beauverilide a","Alias": "NA","Ingredient_formula": "C31H49N3O5","Ingredient_Smile": "CCCCCCC(C)C1CC(=O)NC(C(=O)NC(C(=O)NC(C(=O)O1)C(C)CC)CC2=CC=CC=C2)C(C)C","Ingredient_weight": "543.7 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "2189","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "102059832","DrugBank_id": "NA"}